

Mail Stop MISSING PARTS Commissioner for Patents

P.O. Box 1450

Alexandria, VA 223 3-1450 on July 15, 2004.

Rod D. Baker, Reg. No. 35,434

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/815,198

Applicant

William A. Palmisano and Steven A. Belinsky

Filed

March 25, 2004

Title

CANCER MONITORING BY ABERRANT PROMOTOR METHYLATION OF THE TRANSCRIPTION FACTOR GENES PAX5 ALPHA, PAX5 BETA, NOVEL LOOP HELIX PROTEIN, NOVEL GENE2 AND BETA3

GENES

TC/A.U.

1645

Examiner

Unknown

Docket No.

41543 US 0103

Confirmation No.

8645

Mail Stop: MISSING PARTS
Commissioner for Patents
United States Patent and Trademark Office
PO Box 1450

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 submitted herewith. A copy of each of the listed article references is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior references" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed within three months of the filing date of the application or prior to the mailing date of a first Office action. Therefore, no fee or certification is required. 37 C.F.R. § 1.97(b).

Rod D. Baker, Reg. No. 35,434 Direct line: (505) 998-1504

Enclosures: PTO Form(s) 1449;

Copy of Reference(s)

Peacock, Myers & Adams, P.C. Attorneys for Applicant P.O. Box 26927 Albuquerque, NM 87125-6927 (505) 998-1500 FAX (505) 243-2542 Customer No. 005179

Approved for use through 10-31-99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork	Reduction	Act of 1995	no perso	ns are requ	ired to respo	ond to	a collection of in	formation unless it co	ontains a valid OMB con	itrol number.
Substitute for fo	orm 1449	A/PTO				_	COMPLE	TE IF KNOWN		
INFORMA							Application Number 10/815,198 Filing Date March 25, 2004			
STATEME	ENT B	Y APP	LICA	NT					March 25, 2004	
I.P.E (USA)	s many she	ets as nec	essary)				First Named	Inventor	PALMISANO	O et al
19204					Group Art U	Jnit	1645			
. Sice	1						Examiner N	ame		
& TANGERARY	1		of	5	-		Attorney Do	cket Number	41543 US 010	03
U.S. PATENT	DOCUM	IENTS								
Examiner Initials	Cite No. ¹	<u>U</u> Numbe	Kind	t Docum Code (if know			Name of Pa Applicant Docur	of Cited	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,017	,704	Α		Hei	rman, et al.	_	01/25/2000	
		5,786	,146	A		Hei	rman, et al.		07/28/1998	
								,		
FOREIGN PA	TENT D	OCUME	ENTS							
Examiner Initials	Cite I No.	_F Office ³	-		Code Code Strong		Name of Pa Applicant Docum	of Cited	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear T
Examiner Signature						·		Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $[G:\label{lem:conditional} [G:\label{lem:conditional} [ANNETTE\label{lem:conditional} LRRI-BelinskyPAX5_1449p1.PTO.doc]$

^{1.} Unique citation designation number. 2. See attached Kinds of U.S. Patent Documents. 3. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)

Approved for use through 10-31-99. OMB 0651-003

ripproved	ioi use unough 10	,,-,,	. OMD 0031-003	
Patent and	Trademark Office:	U.S.	DEPARTMENT	OF COMMERCE

Under the Pap	perwork R	eduction Act of	of 1995, no pers	ons are required to respond to a collection of	information unless it contains a valid OMB control number.		
Substitute for form 1449B/PTO				COMPLETE IF KNOWN	COMPLETE IF KNOWN		
INFOR)	ים אחני	SCLOSURE	Application Number	10/815,198		
			PPLICANT	Filing Date	March 25, 2004		
,				First Named Inventor	PALMISANO et al		
('	use as ma	ny sheets as ne	ecessary)	Group Art Unit	1645		
				Examiner Name			
Sheet	2	of	5	Attorney Docket Number	41543 US 0103		

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ANTEGUERA, F., et al., "CpG Islands," DNA Methylation: Molecular Biology and Biological Significance, Ed by J.P. Jost & H.P Saluz, Birkhauser Verag Basel/Switzerland, Vol. 64 pp 169-185 1993	
		BAYLIN, S.B., et al., "DNA Hypermethylation in Tumorigenesis," <i>Trends in Genetics</i> , Vol. 16 pp 168-174, 2000	
		BELINSKY, S.A., et al., "Aberrant Methylation of p16 ^{INK4a} is an Early Event in Lung Cancer and a Potential Biomarker for Early Diagnosis," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 95, pp 11191-11896 Sep 1998	
		BROCK, G.J.R., et al., "A Novel Technique for the Identification of CpG Islands Exhibiting Altered Methylation Patterns (ICEAMP)", <i>Nucleic Acids Research</i> , Vol. 29, No. 24e 2001	
	_	BURBEE, D.G., et al., "Epigenetic Inactivation of RASSSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression," <i>J of Natl Canc Inst</i> , Vol. 93, No. 9, pp 691-699 2001	
		BUSSLINGER, M., et al., "Deregulation of <i>PAX-5</i> by Translocation of the Eμ Enhancer of the <i>IgH</i> Locus Adjacent to Two Alternative <i>PAX-5</i> Promoters in a Diffuse Large-cell Lymphoma," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 93, pp 6129-6134 June 1996	
		CARTER, M.G., et al., "Mice Deficient in the Candidate Tumor Suppressor Gene <i>Hic1</i> Exhibit Development Defects of Structures Affected in the Miller-Dieker Syndrome," <i>Human Molecular Genetics</i> , Vol. 9, No. 3, pp 413-419 2000	
		DU, Y., et al., "Hypermethylation in Human Cancers of the RIZ1 Tumor Suppressor Gene, a Member of a Histone/Protein Methyltransferase Superfamily," Cancer Research, Vol. 61, pp 8094-8099 Nov 15 2001	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\ANNETTE\LRRI-BelinskyPAX5_1449p2.PTO.doc]

Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-96)
Approved for use through 10-31-99. OMB 0651-003	ĺ

	THE THE PROPERTY OF THE PROPERTY OF COMMENCE
persons are required to respond	to a collection of information unless it contains a valid OMB control number

Under the Pap	erwork R	eduction Act o	of 1995, no per	sons are required to respond to a collection of i	information unless it contains a valid OMB control number.		
Substitute for form 1449B/PTO				COMPLETE IF KNOWN	COMPLETE IF KNOWN		
INFOR	МАТ	'ION DI	SCLOSURE	Application Number	10/815,198		
			PPLICANT	Filing Date	March 25, 2004		
,				First Named Inventor	PALMISANO et al		
(1	ise as mai	ny sheets as ne	ecessary)	Group Art Unit	1645		
				Examiner Name			
Sheet	3	of	5	Attorney Docket Number	41543 US 0103		

OTHER PR	IOR ART -	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		COSTELLO, J.R., et al., "Aberrant CpG-Island Methylation has Non-Random and Tumour-type-specific Patterns," <i>Nature Genetics</i> , Vol. 25, pp 132-138 Feb 2000	
		ESTELLER, M., et al., "A Gene Hypermethylation Profile of Human Cancer," <i>Cancer Research</i> , Vol. 61, pp 3225-3229 Apr 15 2001	
		ESTELLER, M., et al., "Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serus DNA from Non-Small Cell Lung Cancer Patients," <i>Cancer Research</i> , Vol. 59, pp 67-70 Jan 1 1999	
		ESTELLER, M., et al., "Inactivation of the DNA Repair Gene O ⁶ -Methylguanine-DNA Methytransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia," Cancer Research, Vol. 59, pp 793-797 Feb 15 1999	
		GARDINER-GARDEN, M., et al., "CpG Islands in Vertegrate Genomes," J. Mol. Biol., Vol. 196, pp 261-282 1987	
		GONZALGO, M.L., et al., "Identification and Characterization of Differentially Methylated Regions of Genomic DNA by Methylation-sensitive Arbitrarily Primed PCR," Cancer Research, Vol.57, pp 5940599 Feb 15 1997	
		HUANG, T.H-M, et al., "Identification of DNA Methylation Markers for Human Breast Carcinomas Using for Methylation-Sensitive Restriction Fingerprinting Technique," Cancer Research, Vol. 57 pp 1030-1034 Mar 15 1997	
		ISSA, J-P J., et al., "H1C1 Hypermethylation is a Late Event in Hematopoietic Neoplasms," Cancer Research, Vol. 57 pp 1678-1681 May 1 1997	

Examiner	Date	·	
Signature	 Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\ANNETTE\LRRI-BelinskyPAX5_1449p3.PTO.doc]

¹ Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

	PTO/SB/08B	(10-96)
oved for use through 1	I0-31-99 OMB 0651-003	

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Olider the Pap	erwork R	eduction Act of	i 1995, no persor	is are required to respond to a collection of in	iformation unless it contains a valid OMB control number.	
Substitu	te for f	form 1449	B/PTO	COMPLETE IF KNOWN		
INFOR	МАТ	יות אחוי	SCLOSURE	Application Number	10/815,198	
			PPLICANT	Filing Date	March 25, 2004	
				First Named Inventor	PALMISANO et al	
(1	use as mai	ny sheets as ne	ccessary)	Group Art Unit	1645	
				Examiner Name		
Sheet	4	of	5	Attorney Docket Number	41543 US 0103	

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		JOHNSON, D.H., et al., "Recent Advances with Chmotherapy for NSCLC: The ECOG Experience," Oncology, Vol. 12, No. 1, Suppl 2 pp 67-70 Jan 1998	
		JONES, P.A., et al., "Cancer Epigenetics Comes of Age," Nature Genetics, Vol. 21 pp 163-167 Feb 1999	
		PALMISANO, W.A., et al., "Aberrant Promoter Methylation of the Transcription Factor Genes PAX5 α and β in Human Cancers," <i>Cancer Research</i> Vol. 63 pp 4620-4625 Aug 1 2003	
		PALMISANO, W.A., et al., "Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum," Cancer Research Vol. 60 pp5954-5958 Nov 1 2000	
		SALEM, C.E., et al., "PAX6 Methylation and Ectopic Expression in Human Tumor Cells," Int. J. Cancer Vol 87 pp 179-185 2000	
		SCHÄFER, B.W., "Emerging Roles for PAX Transcription Factors in Cancer Biology," <i>Gen. Physiol. Biophys</i> Vol 17 pp 211-224 1998	
		SILVA, J.M., et al., "Persistence of Tumor DNA in Plasma of Breast Cancer Patients After Mastectomy," <i>Annals of Surgical Oncology</i> Vol 9, No. 1 pp 71-76 2002	
		STUART E.T., et al., "Loss of p53 Function Through PAX-Mediated Transcriptional Repression," <i>The EMBO Journal</i> Vol. 14, No. 22 pp 5638-5645 1995	
		STUART, E.T., et al., "PAX and HOX IN Neoplasia," Advances in Genetics Vol 33 pp 255-275 1995	

Examiner	Date Considered	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $[G:\label{lem:conditional} [G:\label{lem:conditional} [G:\label{lem:conditional} ANNETTE\label{lem:conditional} LRRI-BelinskyPAX5_1449p4.PTO.doc]$

¹ Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

	PTO/SB/08B	(10-96)
_		, ,

Approved for use through 10-31-99. OMB 0651-003
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork	Reduction Act	of 1995, no pers	ons are required to respond to a collection of in	mark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.	
Substitute for	form 1449		COMPLETE IF KNOWN		
INFORMATION DISCLOSURE			Application Number	10/815,198	
STATEMENT BY APPLICANT		Filing Date	March 25, 2004		
(usa as n	(use as many sheets as necessary)	First Named Inventor	PALMISANO et al		
(use as many sheets as necessary)			Group Art Unit	1645	
			Examiner Name		
Sheet 5	of	5	Attorney Docket Number	41543 US 0103	

Examiner	Cite	Include come of the city of Control of the city of the
Initials	No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		TESTA, J.R., et al., "Cytogenic Analysis of 63 Non-Small Cell Lung Carcinomas: Recurrent Chromosome Alterations Amid Frequent and Widespread Genomic Upheaval," Genes, Chromosomes & Cancer, Vol. 11 pp 178-194 1994
		TOYOOKA, K.O., et al., "Loss of Expression and Aberrant Methylation of the CDH13 (H-Cadherin) Gene in Breast and Lung Carcinomas," Cancer Research Vol 61 pp 4556-4560 June 1 2001
		TOYOTA, M., et al., "Identification of Differentially Methylated Sequences in Colorectal Cancer by Methylated CpG Island Amplification," Cancer Research Vol. 59 pp 2307-2312 May 15 1999
		TOYOTA, M., et al., "CpG Island Methylator Phenotype in Colorectal Cancer," <i>Proc. Natl Acad Sci USA</i> Vol 96 pp 8681-8686 July 1999
		TOYOTA, M., et al., "Inactivation of <i>CACNAIG</i> , A t-Type Calcium Cannel Gene, by Aberrant Methylation of its 5' CpG Island in Human Tumors," <i>Cancer Research</i> Vol 59 pp 4535-4541 Sep 1 1999
		WALES, M.M., et al., "p53 Activates Expression of HIC-1, A New Candidate Tumour Supressor Gene on 17p13.3," Nature Medicine, Vol 1 No 6 pp570-577 June 1995
		YAN, P.S., et al., "Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays," Cancer Research Vol 61 pp 8375-8380 Dec 1 2001
		YANG, X., et al., "DNA Methylation in Breast Cancer," Endocrin-Related Cancer, Vol. 8, pp 115-127 2001
		ZÖCHBAUER-MÜLLER, S., et al., "5' CpG Island Methylation of the <i>fhit</i> Gene is Correlated with Loss of Gene Expression in Lung and Breast Cancer," Cancer Research Vol 61, pp 3581-3585 May 1 2001
		ZOU, H-Z, et al., "Detection of Aberrant p16 Methylation in the Serum of Colorectal Cancer Patients," Clinical Cancer Res, Vol. 8, pp 188-191 Jan 2002
Examiner Signature		Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\ANNETTE\LRRI-BelinskyPAX5_1449p5.PTO.doc]

Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.